229500.Kn
The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of biopharmaceutical products.
Business. The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of biopharmaceutical products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of biopharmaceutical products.
The company's capital structure is characterized by a low debt-to-equity ratio of 0.04, indicating a conservative approach to leverage. With total equity of 3,592,612,440 KRW and total liabilities of 770,110,120 KRW, the company maintains a strong equity base. The current ratio of 1.83 suggests that the company has sufficient current assets to cover its current liabilities, supporting its liquidity position.
Profitability metrics reveal a challenging financial situation. The company reported a net loss of 10,447,517,970 KRW and an operating loss of 5,367,108,580 KRW, indicating significant operational inefficiencies. The return on equity of -2.9081 and return on assets of -2.3947 further underscore the company's inability to generate returns from its equity and asset base.
The company's revenue is not segmented by geographic regions or product lines in the provided data, making it difficult to assess geographic or segment concentration. However, the lack of detailed segment data suggests that the company may be heavily reliant on a single product or market.
The company's growth trajectory is currently negative, with a significant decline in operating and net income. The operating cash flow of -3,358,353,150 KRW and free cash flow of -10,237,991,140 KRW indicate a substantial cash outflow, which could hinder future growth initiatives. The capital expenditure of -80,730,170 KRW suggests that the company is not investing heavily in new projects or infrastructure.
Risk factors include a low liquidity score, which, while not immediately critical, indicates potential challenges in meeting short-term obligations. The company's dilution risk is also low, with no immediate filing-based flags detected. However, the significant net loss and negative cash flows suggest that the company may need to raise additional capital in the future, which could lead to dilution.
Recent events and filings do not indicate any major changes or developments that would significantly impact the company's financial position. The absence of detailed segment and geographic data in the filings suggests that the company may not have a diversified revenue base, which could increase its exposure to market-specific risks.
- The company has a conservative capital structure with a low debt-to-equity ratio.
- The company is experiencing significant operational losses and negative returns on equity and assets.
- The company's liquidity position is adequate, but its negative cash flows could impact future operations.
- The company's growth trajectory is currently negative, with substantial cash outflows.
- The company's risk profile is low in terms of liquidity and dilution, but its financial performance is concerning.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 229500.KN Market data — financials · 2026-05-26